JohnL.WagnerMD

Oncology • Charlottesville, VA

Hematologic Oncology

Hematopoietic Stem Cell Transplantation/ Univ of Virginia Healthcare

Join to view full profile

Dr. Wagner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wagner's full profile

Already have an account?

Office
1240 Lee St
Charlottesville, VA 22908
Phone+1 434-924-9333

Fax+1 434-244-7526

Summary

Dr. John Wagner is an oncologist in Charlottesville VA and is affiliated with Thomas Jefferson University Hospitals. He received his medical degree from Temple University School of Medicine and has been in practice 28 years. He specializes in cellular therapy and hematopoietic stem cell transplantation and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and CAR-T therapy.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1992 - 1995
University of MarylandResidency, Internal Medicine, 1989 - 1992
Lewis Katz School of Medicine at Temple UniversityClass of 1989

Certifications & Licensure

VA State Medical License 2022 - 2026
WV State Medical License 2023 - 2025
PA State Medical License 1999 - 2024
DE State Medical License 2017 - 2023
NJ State Medical License 2017 - 2023
MD State Medical License 1990 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2020-2022
Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013

Clinical Trials

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Start of enrollment: 2005 Nov 01
Completed
Phase 2
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation Start of enrollment: 2004 Mar 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2009 Feb 05
Completed
Phase 2
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies Start of enrollment: 2008 Apr 10
Completed
Phase 2
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Start of enrollment: 2010 May 01
Completed
Phase 2
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors Start of enrollment: 2011 Feb 10
Completed
Phase 2
Treatment of Sickle Cell Anemia With Stem Cell Transplant Start of enrollment: 2009 Sep 01
Terminated
Not Applicable
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Start of enrollment: 2011 May 25
Terminated
Phase 1
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Start of enrollment: 2011 Aug 04
Completed
Phase 2
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09
Completed
Phase 1, Phase 2
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant Start of enrollment: 2012 Aug 01
Withdrawn
Not Applicable
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Start of enrollment: 2012 Dec 24
Completed
Phase 2
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Mar 15
Completed
Early Phase 1
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
Active, not recruiting
Phase 2
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2013 May 17
Terminated
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor Start of enrollment: 2013 Nov 04
Completed
Phase 2
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2014 Aug 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

74 citations
Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee
Lorna J. Kennedy, J. M. Angles, A. Barnes, Stuart D. Carter, Olga Francino
Tissue Antigens. 1999-09-01
39 citations
Nomenclature for factors of the dog major histocompatibility system (DLA), 1998. First report of the ISAG DLA Nomenclature Committee. International Society for Animals...
Lorna J. Kennedy, Laura Altet, J. M. Angles, A. Barnes, Stuart D. Carter
Tissue Antigens. 1999-09-01
11 citations
The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Ste...
Dolores Grosso, Benjamin E. Leiby, Matthew Carabasi, Joanne Filicko-O'Hara, Sameh Gaballa
Frontiers in Oncology. 2019-09-17

Grant Support

Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1999–2001
Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1997–1999